BofA Securities Reiterates Neutral Rating on Biogen (BIIB) as Leqembi Ad Comm briefing doc suggests label restriction overhang removed
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham reiterated a Neutral rating and $320.00 price target on Biogen (NASDAQ: BIIB)."Biogen’s Alzheimer’s (AD) drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
